VistaGen Therapeutics, Inc.VTGNNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
36.28%
↑ 170% above average
Average (39q)
13.44%
Historical baseline
Range
High:121.36%
Low:-55.05%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 36.28% |
| Q2 2025 | 14.41% |
| Q1 2025 | -9.71% |
| Q4 2024 | 10.67% |
| Q3 2024 | 33.56% |
| Q2 2024 | 2.84% |
| Q1 2024 | 63.89% |
| Q4 2023 | 17.83% |
| Q3 2023 | -8.24% |
| Q2 2023 | -55.05% |
| Q1 2023 | 36.23% |
| Q4 2022 | -46.85% |
| Q3 2022 | -15.67% |
| Q2 2022 | 29.91% |
| Q1 2022 | 51.29% |
| Q4 2021 | -21.70% |
| Q3 2021 | 82.08% |
| Q2 2021 | 11.58% |
| Q1 2021 | 39.90% |
| Q4 2020 | 48.25% |
| Q3 2020 | 36.22% |
| Q2 2020 | -5.94% |
| Q1 2020 | -38.94% |
| Q4 2019 | -28.31% |
| Q3 2019 | -2.52% |
| Q2 2019 | 14.79% |
| Q1 2019 | -29.56% |
| Q4 2018 | 1.41% |
| Q3 2018 | 91.75% |
| Q2 2018 | 4.01% |
| Q1 2018 | 64.68% |
| Q4 2017 | -33.99% |
| Q3 2017 | 121.36% |
| Q2 2017 | -5.57% |
| Q1 2017 | -27.94% |
| Q4 2016 | 0.31% |
| Q3 2016 | 94.51% |
| Q2 2016 | -24.70% |
| Q1 2016 | 36.00% |
| Q4 2015 | -51.31% |